Pulmonary and Allergy Drugs Advisory Committee January 17, 2002 Pulmonary and Allergy Drugs Advisory Committee Meeting Gaithersburg, Maryland January 17,

Slides:



Advertisements
Similar presentations
GOLD MANAGEMENT PLAN FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
Advertisements

TROPHY TRial Of Preventing HYpertension. High-normal BP increases CV risk Vasan RS et al. N Engl J Med. 2001;345: Incidence of CV events in women.
1 Efficacy of Testosterone Transdermal System (TTS) for Treatment of HSDD in Surgically Menopausal Women on Concomitant Estrogen Daniel Davis, MD, MPH.
S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Heart rate reduction with ivabradine and health related quality of life in.
1 OTC Omeprazole Magnesium (Prilosec 1 TM ) October 20, 2000 Larry Goldkind MD Division of Gastrointestinal and Coagulation Drug Products CDER, FDA.
1 Tolvaptan for the Treatment of Hyponatremia Aliza Thompson, MD Medical Officer Cardiovascular and Renal Drugs Advisory Committee Meeting June 25, 2008.
Afrezza® – inhaled human insulin
Bepotastine Besilate Ophthalmic Solution 1.5% and Degree of Reduced Ocular Itching in a Conjunctival Allergen Challenge Test JI Williams 1, G Torkildsen.
Treatment for Adolescents With Depression Study (TADS)
Respiratory COPD/Asthma.
Budesonide/formoterol as effective as prednisolone plus formoterol in acute exacerbations of COPD A double-blind, randomised, non-inferiority, parallel-group,
CHEST. 2007;131(4): Methylprednisolone Infusion in Early Severe ARDS - Results of a Randomized Controlled Trial.
Food and Drug Administration Division of Pulmonary and Allergy Drug Products Pulmonary-Allergy Drugs Advisory Committee Meeting July 13, 2005 Safety of.
Diabetes Mellitus 101 for Medical Professionals An Aggressive Pathophysiologic Approach to Cardiometabolic Therapy for Type 2 Diabetes: Stan Schwartz MD,FACP.
Pulmonary and Allergy Drugs Advisory Committee Thursday, 17 January 2002 ADVAIR and FLOVENT DISKUS Supplements for the COPD indication: SUMMARY and QUESTIONS.
Pulmonary-Allergy Drugs Advisory Committee January 17, FLOVENT ® DISKUS ® NDA , S004 GlaxoSmithKline Pulmonary-Allergy Drugs Advisory Committee.
CLAIMS STRUCTURE FOR SLE Jeffrey Siegel, M.D. Arthritis Advisory Committee September 29, 2003.
Pulmonary-Allergy Drugs Advisory Committee September 6, 2002 Pulmonary-Allergy Drugs Advisory Committee NDA Spiriva ® (tiotropium bromide) Inhalation.
1 ENTEREG ® (Alvimopan) Special Safety Section Marjorie Dannis, M.D. Division of Gastroenterology Products Office of Drug Evaluation III CDER, FDA The.
Definition COPD def- A disease state characterized by air flow limitation that is not fully reversible It is expected to be the 3 rd leading cause of.
Food and Drug Administration Division of Pulmonary and Allergy Drug Products Endocrine and Metabolic Drugs Advisory Committee Meeting - Human Recombinant.
CS-1 Safety of Foradil ® Gregory P. Geba, MD, MPH Vice President – US Head RDI Clinical Development and Medical Affairs Novartis Gregory P. Geba, MD, MPH.
CE-1 IRESSA ® Clinical Efficacy Ronald B. Natale, MD Director Cedars Sinai Comprehensive Cancer Center Ronald B. Natale, MD Director Cedars Sinai Comprehensive.
Pulmonary-Allergy Drugs Advisory Committee May 1, 2007 FDA Presentation Advair Diskus 500/50 Carol Bosken, MD, ScM, MPH Medical Officer Division of Pulmonary.
Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 2 ARBITER-2 Trial Presented at The American Heart Association Scientific.
GOLD Update 2011 Rabab A. El Wahsh, MD. Lecturer of Chest Diseases and Tuberculosis Minoufiya University REVISED 2011.
Food and Drug Administration Center for Drug Evaluation and Research Lessons Learned from Growth Studies with Orally Inhaled and Intranasal Corticosteroids.
Sertraline Use in Pediatric Population: A Risk Benefit Discussion Steven J. Romano, MD September 13, 2004 Steven J. Romano, MD September 13, 2004 Joint.
Joint NDAC/DODAC Advisory Committee Meeting March 24, 2005 Rx Topical Corticosteroids and Testing for Adrenal Suppression Markham C. Luke, M.D., Ph.D.
1 Study Design Issues and Considerations in HUS Trials Yan Wang, Ph.D. Statistical Reviewer Division of Biometrics IV OB/OTS/CDER/FDA April 12, 2007.
Pulmonary-Allergy Drugs Advisory Committee September 6, SGRQSGRQ 3 Domains: –Symptoms: cough, sputum production, wheeze, breathlessness, duration.
Teriparatide or LY Eli Lilly & Company NDA Metabolic-Endocrine Drugs Metabolic-Endocrine Drugs Advisory Committee Advisory Committee Bethesda,
1 Markham C. Luke, M.D., Ph.D. Dermatology Clinical Team Leader DDDDP, ODE V, CDER, FDA Combination Topical Products for the Treatment of Acne Vulgaris.
CV-1 Trial 709 The ISEL Study (IRESSA ® Survival Evaluation in Lung Cancer) Summary of Data as of December 16, 2004 Kevin Carroll, MSc Summary of Data.
A 1 Pulmonary - Allergy Drugs Advisory Committee Meeting January 17, 2002 FLOVENT® DISKUS® NDA ADVAIR DISKUS® NDA
Conclusions Sidney Cohen, MD Chairman, Department of Medicine Temple University School of Medicine Philadelphia, Pennsylvania Sidney Cohen, MD Chairman,
COPD ) ) Chronic Obstructive Pulmonary Disease. Introduction n COPD is a preventable and treatable disease with some significant extrapulmonary effects.
Acute Bacterial Otitis Media Summary and Charge to the Committee Renata Albrecht, M.D. Division of Special Pathogen and Immunologic Drug Products ODEIV,
Food and Drug Administration Division of Pulmonary and Allergy Drug Products Summary Comments - Orally Inhaled and Intranasal Budesonide and Fluticasone.
Long-Term Tolerability of Ticagrelor for Secondary Prevention: Insights from PEGASUS-TIMI 54 Trial Marc P. Bonaca, MD, MPH on behalf of the PEGASUS-TIMI.
Long-Term Tolerability of Ticagrelor for Secondary Prevention: Insights from PEGASUS-TIMI 54 Trial Marc P. Bonaca, MD, MPH on behalf of the PEGASUS-TIMI.
Pulmonary-Allergy Drugs Advisory Committee May 1, 2007 OutlineOutline History of development programHistory of development program –Dr. Carol Bosken Introduction.
ASCEND-HF Acute Study of Clinical Effectiveness of Nesiritide in Subjects with Decompensated Heart Failure Duke Heart Failure Research Pager:
CLINICAL EFFICACY Oral Telithromycin George Rochester, PhD, CCRN Statistical Reviewer Division of Biometrics III Division of Anti-infective Drug Products.
Lancet Respir Med 2013; 1: 199–209 R4.신재령 / Prof. 박명재
LSU Journal Club Withdrawal of Inhaled Glucocorticoids and Exacerbations of COPD WISDOM study H. Magnussen MD, et al. Nisha Loganantharaj, PGY1 April 21,
내과 R2 이지훈 N Engl J Med Sep 8.
R3 정수웅. Introduction Community-acquired pneumonia − Leading infectious cause of death in developed countries − The mortality in patients with treatment.
Joint Non-Prescription Drugs and Pediatric Advisory Committee Meeting October 18-19, 2007 Considerations for Extrapolation of Efficacy from Adults to Children.
Analysis of chronic obstructive pulomnary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK):
Management of stable chronic obstructive pulmonary disease (2) Seminar Training Primary Care Asthma + COPD D.Anan Esmail.
Patient-Reported Outcome (PRO) Claims in Products Approved For Chronic Obstructive Pulmonary Disease (COPD) in Europe and the USA Martine Caron, Laure-Lou.
CHEST 2014; 145(4): 호흡기내과 R3 박세정. Cigarette smoking ㅡ the most important risk factor for COPD in the US. low value of FEV 1 : an independent predictor.
A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis N ENGL J MED. May 18, /NEJMoa Talmadge E. King, Jr., M.D.,
Opiate Therapy in Chronic Cough Alyn H. Morice, Madhav S. Menon, Siobhan A. Mulrennan, Caroline F. Everett, Caroline Wright, Jennifer Jackson and Rachel.
1 Once-daily indacaterol versus twice-daily salmeterol for COPD ; a placebo-controlled comparison R2 정명화 Eur Respir J 2011; 37: 273–279.
CHEST 2013; 144(3): R3 김유진 / Prof. 장나은. Introduction 2  Cardiovascular diseases  common, serious comorbid conditions in patients with COPD cardiac.
Powered by Infomedica Infomedica Conference Coverage* of 26 th European Meeting on Hypertension and Cardiovascular Protection Paris (France), June 10-13,
External multicentric validation of a COPD detection questionnaire.
Nymox Pivotal Phase 3 Fexapotide (NX-1207) BPH Extension Trial Successfully Meets Primary Endpoint
Neal B, et al. Diabetes Care 2015;38:403–411
Alan Kaplan MD CCFP(EM) FCFP Family Physician Airways Group of Canada
Volume 143, Issue 6, Pages (June 2013)
The Safety and Efficacy of Full vs
Combination Inhaled Therapy in COPD: The Impact of Recent Data
Volume 152, Issue 6, Pages (December 2017)
Change from baseline in (A) E-RS total score and (B) E-RS cough and sputum domain score over the study period in ATTAIN and the active-comparator study.
The efficacy and safety of omalizumab in pediatric allergic asthma
Gregory Levin, FDA/CDER/OTS/OB/DBIII
Eugenio Andraca-Carrera
Presentation transcript:

Pulmonary and Allergy Drugs Advisory Committee January 17, 2002 Pulmonary and Allergy Drugs Advisory Committee Meeting Gaithersburg, Maryland January 17, 2002 Lydia I. Gilbert-McClain, MD, FCCP Medical Reviewer, DPADP Pulmonary and Allergy Drugs Advisory Committee Meeting Gaithersburg, Maryland January 17, 2002 Lydia I. Gilbert-McClain, MD, FCCP Medical Reviewer, DPADP ADVAIR TM DISKUS (R) (Fluticasone propionate/salmeterol inhalation powder)

Pulmonary and Allergy Drugs Advisory Committee January 17, CLINICAL ISSUES Clinical relevance of the Efficacy data Application of data from these ADVAIR trials to the general COPD population Adequacy of the Safety data Clinical relevance of the Efficacy data Application of data from these ADVAIR trials to the general COPD population Adequacy of the Safety data

Pulmonary and Allergy Drugs Advisory Committee January 17, COMBINATION DRUG PRODUCT Not approved for use in COPDApproved Relief of bronchospasm associated with COPD ADVAIR DISKUS Fluticasone propionateSalmeterol xinafoate

Pulmonary and Allergy Drugs Advisory Committee January 17, DEVELOPMENT PROGRAM

Pulmonary and Allergy Drugs Advisory Committee January 17, OBJECTIVESOBJECTIVES 1. Efficacy of ADVAIR 250/50 bid and ADVAIR 500/50 bid 2. Safety of ADVAIR 250/50 bid and ADVAIR 500/50 bid 3.The “ quality of life” in COPD subjects receiving ADVAIR 250/50 bid and ADVAIR 500/50 bid 1. Efficacy of ADVAIR 250/50 bid and ADVAIR 500/50 bid 2. Safety of ADVAIR 250/50 bid and ADVAIR 500/50 bid 3.The “ quality of life” in COPD subjects receiving ADVAIR 250/50 bid and ADVAIR 500/50 bid

Pulmonary and Allergy Drugs Advisory Committee January 17, FIXED COMBINATION DRUGS POLICY  21 CFR Two or more drugs may be combined in a single dosage form when:  Each component makes a contribution to the claimed effects  The combination is safe and effective  SFCA3006, SFCA3007 adequately designed to fulfill the efficacy requirements of the policy  21 CFR Two or more drugs may be combined in a single dosage form when:  Each component makes a contribution to the claimed effects  The combination is safe and effective  SFCA3006, SFCA3007 adequately designed to fulfill the efficacy requirements of the policy

Pulmonary and Allergy Drugs Advisory Committee January 17, ENTRY CRITERIA Diagnosis of COPD [ATS definition] Must have a history of cough productive of sputum on most days for at least 3 months of the year for at least 2 years that was not attributable to another disease process Baseline FEV 1 of 0.70 L OR FEV 1  0.70 L AND > 40% < 65% predicted AND FEV 1 /FVC ratio  70% Diagnosis of COPD [ATS definition] Must have a history of cough productive of sputum on most days for at least 3 months of the year for at least 2 years that was not attributable to another disease process Baseline FEV 1 of 0.70 L OR FEV 1  0.70 L AND > 40% < 65% predicted AND FEV 1 /FVC ratio  70%

Pulmonary and Allergy Drugs Advisory Committee January 17, PATIENT POPULATION ENROLLED Mean FEV 1 across studies was 40% - 42% predicted Mean FEV 1 /FVC ratio across studies was 47% - 51% Percentage of subjects across studies with 12% improvement in FEV 1 AND >200 ml absolute change was 54% - 55% Mean FEV 1 across studies was 40% - 42% predicted Mean FEV 1 /FVC ratio across studies was 47% - 51% Percentage of subjects across studies with 12% improvement in FEV 1 AND >200 ml absolute change was 54% - 55%

Pulmonary and Allergy Drugs Advisory Committee January 17, PATIENT POPULATION ENROLLED All subjects had a history of chronic bronchitis Mean baseline symptom score on Chronic Bronchitis Symptom Questionnaire ranged [maximum possible score = 16] Dyspnea score  2 [scale 0 - 4] All subjects had a history of chronic bronchitis Mean baseline symptom score on Chronic Bronchitis Symptom Questionnaire ranged [maximum possible score = 16] Dyspnea score  2 [scale 0 - 4]

Pulmonary and Allergy Drugs Advisory Committee January 17, Percentage of Discontinuations

Pulmonary and Allergy Drugs Advisory Committee January 17, PRIMARY EFFICACY ENDPOINTS Pre-dose FEV 1  Evaluate the contribution of FP in the combination  ADVAIR vs. Salmeterol  2-hr post-dose FEV 1  Evaluate the contribution of salmeterol in the combination  ADVAIR vs. FP Pre-dose FEV 1  Evaluate the contribution of FP in the combination  ADVAIR vs. Salmeterol  2-hr post-dose FEV 1  Evaluate the contribution of salmeterol in the combination  ADVAIR vs. FP

Pulmonary and Allergy Drugs Advisory Committee January 17, EFFICACY: Pre-dose FEV 1

Pulmonary and Allergy Drugs Advisory Committee January 17, EFFICACY: 2-hr Post-Dose FEV 1

Pulmonary and Allergy Drugs Advisory Committee January 17, EFFICACY: ADVAIR vs. Placebo (Reversible and Non-reversible populations) Pre-Dose FEV 1

Pulmonary and Allergy Drugs Advisory Committee January 17, EFFICACY: ADVAIR vs. Placebo (Reversible and Non-reversible populations) 2- hour post- dose FEV 1

Pulmonary and Allergy Drugs Advisory Committee January 17, PATIENT-REPORTED OUTCOMES Evaluation of patient-related outcomes may be helpful in assessing the clinical relevance of FEV 1 changes Chronic Respiratory Disease Questionnaire [CRDQ] used in both studies Sponsor-defined Minimal Clinically Important change [MCIC] in Overall Score  10 Evaluation of patient-related outcomes may be helpful in assessing the clinical relevance of FEV 1 changes Chronic Respiratory Disease Questionnaire [CRDQ] used in both studies Sponsor-defined Minimal Clinically Important change [MCIC] in Overall Score  10

Pulmonary and Allergy Drugs Advisory Committee January 17, Chronic Respiratory Disease Questionnaire Overall Score: Treatment Difference in Change From Baseline At Endpoint

Pulmonary and Allergy Drugs Advisory Committee January 17, CRDQ: Dyspnea Domain Treatment Difference in Change from Baseline at Endpoint

Pulmonary and Allergy Drugs Advisory Committee January 17, 2002 COPD EXACERBATIONS  Severity of exacerbations  Time to first exacerbation  Time to first moderate/severe exacerbation  Number of withdrawals due to COPD exacerbations  Severity of exacerbations  Time to first exacerbation  Time to first moderate/severe exacerbation  Number of withdrawals due to COPD exacerbations

Pulmonary and Allergy Drugs Advisory Committee January 17, Percentage of Subjects with COPD Exacerbations

Pulmonary and Allergy Drugs Advisory Committee January 17, Percentage of Subjects with Moderate/Severe Exacerbations

Pulmonary and Allergy Drugs Advisory Committee January 17, Percentage of Withdrawals Due to COPD Exacerbations

Pulmonary and Allergy Drugs Advisory Committee January 17, Chronic Bronchitis Symptoms Questionnaire [CBSQ]  Cough frequency and severity  Chest discomfort  Sputum production  Sponsor-defined MCIC  1.4  Cough frequency and severity  Chest discomfort  Sputum production  Sponsor-defined MCIC  1.4

Pulmonary and Allergy Drugs Advisory Committee January 17, CBSQ GAS: Treatment Difference in Change from Baseline at Endpoint

Pulmonary and Allergy Drugs Advisory Committee January 17, Transitional Dyspnea Index (TDI): Treatment Difference at Endpoint

Pulmonary and Allergy Drugs Advisory Committee January 17, SAFETYSAFETY Incidence of Cardiovascular events similar across treatment groups No clinically significant change in heart rate No drug-related QTc changes Holter monitoring - One case of heart block with ADVAIR 500/50 Incidence of Cardiovascular events similar across treatment groups No clinically significant change in heart rate No drug-related QTc changes Holter monitoring - One case of heart block with ADVAIR 500/50

Pulmonary and Allergy Drugs Advisory Committee January 17, ADVERSE EVENTS Higher percentage of subjects in ADVAIR groups reported adverse events compared to placebo ADVAIR 250/5070% Placebo64% ADVAIR 500/5078% Placebo69% Higher percentage of subjects in ADVAIR groups reported adverse events compared to placebo ADVAIR 250/5070% Placebo64% ADVAIR 500/5078% Placebo69%

Pulmonary and Allergy Drugs Advisory Committee January 17, ADVERSE EVENTS

Pulmonary and Allergy Drugs Advisory Committee January 17, ADVERSE EVENTS

Pulmonary and Allergy Drugs Advisory Committee January 17, OTHER ADVERSE EVENTS Fractures rarely reported No cataracts reported Two reports of ocular pressures disorders in the ADVAIR 500/50 group and one in the placebo group Elevated blood glucose [ > 175 mg/dl] similar in ADVAIR and placebo groups Fractures rarely reported No cataracts reported Two reports of ocular pressures disorders in the ADVAIR 500/50 group and one in the placebo group Elevated blood glucose [ > 175 mg/dl] similar in ADVAIR and placebo groups

Pulmonary and Allergy Drugs Advisory Committee January 17, SAFETY: Evaluation of HPA Axis Effects Mean AM cortisol levels comparable in ADVAIR and placebo groups on Treatment Day 1 and Endpoint No adrenal insufficiency observed with ACTH [Cosyntropin] stimulation testing ACTH stimulation insensitive test for less than complete adrenal insufficiency Mean AM cortisol levels comparable in ADVAIR and placebo groups on Treatment Day 1 and Endpoint No adrenal insufficiency observed with ACTH [Cosyntropin] stimulation testing ACTH stimulation insensitive test for less than complete adrenal insufficiency

Pulmonary and Allergy Drugs Advisory Committee January 17, SUMMARY - EFFICACY ADVAIR 250/50 and ADVAIR 500/50 meet efficacy criteria for combination drugs in the primary endpoints Similar efficacy for ADVAIR 250/50 and ADVAIR 500/50 Numerically, effect size in “Reversible” subjects > effect size of “Non-reversible” subjects ADVAIR 250/50 and ADVAIR 500/50 meet efficacy criteria for combination drugs in the primary endpoints Similar efficacy for ADVAIR 250/50 and ADVAIR 500/50 Numerically, effect size in “Reversible” subjects > effect size of “Non-reversible” subjects

Pulmonary and Allergy Drugs Advisory Committee January 17, SUMMARY - EFFICACY No clear treatment advantage with ADVAIR for  COPD-related “quality of life”  COPD Symptoms  COPD exacerbations  Improvement in dyspnea No clear treatment advantage with ADVAIR for  COPD-related “quality of life”  COPD Symptoms  COPD exacerbations  Improvement in dyspnea

Pulmonary and Allergy Drugs Advisory Committee January 17, SUMMARY - SAFETY  Higher incidence of candidiasis, viral respiratory infections and hoarseness/dysphonia with ADVAIR  No adrenal insufficiency observed with ACTH [Cosyntropin] stimulation testing  Studies not designed to evaluate bone mineral density or ocular effects  Higher incidence of candidiasis, viral respiratory infections and hoarseness/dysphonia with ADVAIR  No adrenal insufficiency observed with ACTH [Cosyntropin] stimulation testing  Studies not designed to evaluate bone mineral density or ocular effects